MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
+$20.9M |
| 2 |
Sutro Biopharma
STRO
|
+$18.1M |
| 3 |
Natera
NTRA
|
+$13M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$11.6M |
| 5 |
89bio
ETNB
|
+$10.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karuna Therapeutics
KRTX
|
+$16.9M |
| 2 |
Cymabay Therapeutics
CBAY
|
+$14.4M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$12.7M |
| 4 |
Structure Therapeutics
GPCR
|
+$9.4M |
| 5 |
Viking Therapeutics
VKTX
|
+$7.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q1 2024 Portfolio in Review
As of Q1 2024, MPM BioImpact held 44 positions worth $622M, up 46% from $427M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
MPM BioImpact deployed $80.5M of net new capital in Q1 2024, opening 12 new positions and adding to 14 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $12.7M trimmed.
- MPM BioImpact's largest Q1 2024 buy was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.
- MPM BioImpact added most to Viridian Therapeutics in Q1 2024, an estimated $10M increase.
- MPM BioImpact's biggest Q1 2024 reduction was Iovance Biotherapeutics, cutting an estimated $12.7M.
- MPM BioImpact fully exited Karuna Therapeutics in Q1 2024, selling an estimated $16.9M.
- MPM BioImpact's ten largest holdings make up 55% of its $622M portfolio in Q1 2024.
- MPM BioImpact opened 12 new positions and closed 6 in Q1 2024.
- MPM BioImpact's portfolio value rose 46% quarter-over-quarter to $622M.
Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.